Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This phase II study aims to explore the efficacy and safety of fruquintinib combined with
TAS-102 in the third-line treatment of patients with advanced metastatic colorectal cancer.